Skip to Main Content


Skip Nav Destination


Research Article March 20 2023
Identification of a First-in-Class Small Molecule Inhibitor of the eIF4E-RBM38 Complex that Enhances wild-type p53 Protein Translation for Tumor Growth Suppression
Mol Cancer Ther MCT-22-0627.
Research Article March 20 2023
Arginase 1/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy
Mol Cancer Ther MCT-22-0721.
Research Article March 15 2023
Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
Mol Cancer Ther MCT-22-0415.
Research Article March 15 2023
3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability
Mol Cancer Ther MCT-22-0352.
Research Article March 13 2023
Comparison of Three Transcytotic Pathways for Distribution to Brain Metastases of Breast Cancer
Mol Cancer Ther MCT-22-0815.
Research Article March 13 2023
Novel arginase inhibitor, AZD0011, demonstrates immune cell stimulation and anti-tumor efficacy with diverse combination partners
Mol Cancer Ther MCT-22-0431.
Research Article March 8 2023
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib Plus Osimertinib in an EGFR-Mutation Positive, MET-Amplified Non-Small Cell Lung Cancer Model
Mol Cancer Ther MCT-22-0193.
Research Article February 23 2023
IMiDs augment CD3-bispecific antibody induced CD8+ cell cytotoxicity and expansion by enhancing IL-2 production
Mol Cancer Ther MCT-22-0498.
Research Article February 20 2023
Tumor and stromal cell targeting with Nintedanib and Alpelisib overcomes intrinsic bladder cancer resistance
Mol Cancer Ther MCT-21-0667.
Research Article February 14 2023
Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death.
Mol Cancer Ther MCT-21-0880.
Research Article February 10 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Mol Cancer Ther MCT-22-0583.
Review Article February 10 2023
Current Status and Challenges of Vaccination Therapy for Glioblastoma
Mol Cancer Ther MCT-22-0503.
Research Article February 10 2023
Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma
Mol Cancer Ther MCT-22-0490.
Research Article February 10 2023
Efficacious Combination Drug Treatment for Colorectal Cancer that Overcomes Resistance to KRAS G12C Inhibitors
Mol Cancer Ther MCT-22-0411.
Research Article February 10 2023
Bepotastine sensitizes ovarian cancer to PARP inhibitors through suppressing NF-κB-triggered SASP in cancer-associated fibroblasts
Mol Cancer Ther MCT-22-0396.
Research Article February 10 2023
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors
Mol Cancer Ther MCT-22-0351.
Research Article February 10 2023
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Mol Cancer Ther MCT-22-0335.
Review Article February 7 2023
Targeting senescence as a therapeutic opportunity for triple-negative breast cancer
Mol Cancer Ther MCT-22-0643.
Research Article February 7 2023
SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models
Mol Cancer Ther MCT-22-0401.
Research Article February 7 2023
Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS
Mol Cancer Ther MCT-22-0191.
Research Article January 31 2023
Payload-binding Fab fragments increase the therapeutic index of MMAE antibody-drug conjugates
Mol Cancer Ther MCT-22-0440.
Research Article January 24 2023
Liposome-encapsulated eribulin shows enhanced antitumor activity over eribulin for combination therapy with anti-PD-1 antibody
Mol Cancer Ther MCT-22-0475.
Research Article January 24 2023
Redundant Signaling as the Predominant mechanism for Resistance to Antibodies Targeting IGF-1R in Cells Derived from Childhood Sarcoma
Mol Cancer Ther MCT-20-0625.
Close Modal

or Create an Account

Close Modal
Close Modal